ABSTRACT
Basal studies have shown that calcitonin gene‐related peptide (CGRP) is a major sensory neuronal messenger in the trigeminovascular system, the pathway conveying intracranial pain. In migraine and cluster headache attacks, CGRP is released in parallel with the pain and successful treatment of the attacks abort both the associated pain and the CGRP release. The search for a potent small molecule CGRP antagonist has been successful and such an agent has been tested in preclinical and clinical studies. The aim of the present study was to examine current knowledge on the clinical pharmacology of systemic BIBN4096BS, which has been shown in man to abort acute migraine attacks as well or better than oral sumatriptan. BIBN4096BS is a specific and potent CGRP receptor antagonist in humans. In safety and tolerability studies the substance is well tolerated with no or only mild side effects. In acute migraine attacks the overall response was 66% with the drug and 27% with placebo. A difference as compared to placebo was seen at 30 min; the response was still rising at 4 h suggesting a long duration of action. At 24 h the pain‐free rate was better than that with triptans, suggesting a lower grade of rebound and perhaps even a prophylactic possibility.
Keywords: BIBN4096BS, CGRP antagonists, Migraine
Full Text
The Full Text of this article is available as a PDF (71.6 KB).
REFERENCES
- 1. Baskaya MK, Suzuki Y, Anzai M, et al. Effects of adrenomedullin, calcitonin gene‐related peptide, and amylin on cerebral circulation in dogs. J Cereb Blood Flow Metab 1995;15:827–834. [DOI] [PubMed] [Google Scholar]
- 2. Brain SD. Calcitonin gene‐related peptide (CGRP) antagonists: Blockers of neuronal transmission in migraine. Br J Pharmacol 2004;142:1053–1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Dodick DW. Introduction: Cardiovascular safety and triptans in the acute treatment of migraine. Headache 2004;44(Suppl 1):S1–S4. [DOI] [PubMed] [Google Scholar]
- 4. Doods H, Hallenmayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420–423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: A new target in the treatment of headache. Cephalalgia 2004;24:611–622. [DOI] [PubMed] [Google Scholar]
- 6. Edvinsson L, Alm R, Shaw D, et al. Effect of the CGRP receptor antagonist BIBN4096Bs in human cerebral, coronary and omental arteries and in SK‐N‐MC cells. Eur J Pharmacol 2002;434:49–53. [DOI] [PubMed] [Google Scholar]
- 7. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Rev 2005;48:In press. [DOI] [PubMed] [Google Scholar]
- 8. Farachi FM, Kadel KA, Heistad DD. Vascular responses of dura mater. Am J Physiol 1989;257:H157–161. [DOI] [PubMed] [Google Scholar]
- 9. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (5‐HT1B/1D agonist) in acute migraine treatment: A meta‐analysis of 52 trials. Lancet 2001;358:1668–1675. [DOI] [PubMed] [Google Scholar]
- 10. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine. Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48–56. [DOI] [PubMed] [Google Scholar]
- 11. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183–187. [DOI] [PubMed] [Google Scholar]
- 12. Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides 2001;22:995–1007. [DOI] [PubMed] [Google Scholar]
- 13. Harper M, Bohlen HG, Rubin MJ. Arterial and microvascular contributions to cerebral cortical autoregulation in rats. Am J Physiol 1984;246:H17–24. [DOI] [PubMed] [Google Scholar]
- 14. Howden CW, Logue C, Gavin K, et al. Haemodynamic effects of intravenous human calcitonin‐gene related peptide in man. Clin Sci 1988;74:413–418. [DOI] [PubMed] [Google Scholar]
- 15. Iovino M, Feifel U, Yong C‐L, et al. Safety, tolerability and pharmacokinetics of BIBN4096BS, the first selective small molecule calcitonin gene‐related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645–656. [DOI] [PubMed] [Google Scholar]
- 16. Juhasz G, Zsombok T, Jakab B, et al. Parallel decrease in plasma calcitonin gene‐related peptide (CGRP) concentration and migraine headache after sumatriptan treatment. Cephalalgia 2005;25:1–2. [DOI] [PubMed] [Google Scholar]
- 17. Juhasz G, Zsombok T, Modos EA, et al. NO‐induced migraine attack: Strong increase in plasma calcitonin gene‐related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003;106:461–470. [DOI] [PubMed] [Google Scholar]
- 18. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54–61. [DOI] [PubMed] [Google Scholar]
- 19. Lind H, Edvinsson L. Enhanced vasodilator responses to calcitonin gene‐related peptide (CGRP) in subcutaneous arteries in human hypertension. J Human Hypertens 2002;16:53–59. [DOI] [PubMed] [Google Scholar]
- 20. MassenVanDenBrink A, Saxena P. Coronary vasoconstrictor potential of triptans: A review of in vitro pharmacologic data. Headache 2004;44(Suppl 1):S13–S19. [DOI] [PubMed] [Google Scholar]
- 21. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene‐related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N Engl J Med 2004;350:1073–1075. [DOI] [PubMed] [Google Scholar]
- 22. Oliver KR, Wainwright A, Edvinsson L, et al. Immunohistochemical localization of calcitonin receptor‐like receptor and receptor activity‐modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 2002;22:620–629. [DOI] [PubMed] [Google Scholar]
- 23. Petersen KA, Birk S, Lassen LH, et al. The novel CGRP‐antagonist, BIBN4096BS does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia 2003;23:729. [DOI] [PubMed] [Google Scholar]
- 24. Petersen KA, Lassen LH, Birk S, et al. The effect of the nonpeptide CGRP‐antagonist, BIBN4096BS on human‐alphaBGRP induced headache and hemodynamics in healthy volunteers. Cephalalgia 2003;23:725. [DOI] [PubMed] [Google Scholar]
- 25. Petersen KA, Schindler M, Doods H, et al. Inhibiting effect of BIBN4096BS on cephalic vasodilatation induced by CGRP and electrical stimulation of dura mater in the rat. Br J Pharmacol 2004;143:697–704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Ray BS, Wolff HG. Experimental studies on headaches, pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813–56. [Google Scholar]
- 27. Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP‐122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double‐blind, placebo‐controlled clinical trials. Ann Neurol 2000;47:238–41. [PubMed] [Google Scholar]
- 28. Struthers AD, Brown MJ, Macdonald DW, et al. Human calcitonin gene related peptide: A potent endogenous vasodilator in man. Clin Sci 1986;70:386–393. [DOI] [PubMed] [Google Scholar]
- 29. Suzuki Y, Satoh S, Ikegaki I, et al. Effects of neuropeptide Y and calcitonin gene‐related peptide on local cerebral blood flow in rat striatum. J Cereb Blood Flow Metab 1989;9:268–270. [DOI] [PubMed] [Google Scholar]
- 30. The International Classification of Headache Disorders. Cephalalgia 2004;24(Suppl 1):1–160. [DOI] [PubMed] [Google Scholar]
- 31. Williamson DJ, Hargreaves RJ, Hill RG, et al. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat — intravital microscope studies. Cephalalgia 1997;17:525–531. [DOI] [PubMed] [Google Scholar]
- 32. Wu D, Eberlein W, Rudolf K, et al. Characterisation of calcitonin gene‐related peptide receptors in rat atrium and vas deferens: Evidence for a [Cys(Et)(2,7)]hCGRP‐preferring receptor. Eur J Pharmacol 2000;400:313–319. [DOI] [PubMed] [Google Scholar]